publication date: Mar. 7, 2014


Pasche Named Director of Wake Forest Cancer Center

BORIS PASCHE has become director of the recently expanded comprehensive cancer center at Wake Forest Baptist Medical Center.

Pasche will be the principal investigator of the center’s NCI core grant, and will serve as chair of the department of Cancer Biology at Wake Forest Baptist. Previously, he was director of the division of hematology/oncology at the University of Alabama at Birmingham.

Pasche identified the first mutation of a gene that controls cell growth and found that some individuals carry an altered form of the gene, which increases their risk of developing several forms of cancer. He also identified one of the first genetic links between obesity and breast and colon cancer.

He has also served as director of the Cancer Genetics program and leader of the Cancer Genes and Molecular Targeting program at the Northwestern University Robert H. Lurie Comprehensive Cancer Center. In 2008, Pasche joined UAB where was a professor of medicine and holder of the Martha Ann and David L. May Endowed Chair in Cancer Research. He also served as associate director for Translational Research and deputy director at the UAB Comprehensive Cancer Center.

Pasche is currently an associate editor for the Journal of the American Medical Association and editor of both The Journal of Experimental and Clinical Cancer Research and Cancer Hallmarks. He has served on numerous study sections and is a permanent member of the NCI Cancer Genetics study section.

The cancer center recently opened after a $125 million capital construction project that began in June 2011, which added an oncology intensive care unit, four inpatient floors, a day … Continue reading 40-10 In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.